Lipid formulations of amphotericin B in the treatment of experimental visceral leishmaniasis due to Leishmania infantum

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 90, Issue 5, 1996, Pages 574-577

  Gangneux, Jean Pierre ^a   Sulahian, Annie ^a   Garin, Yves Jean François ^a   Derouin, Francis ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Abelcet ; AmBisome ; Amphotericin B; Chemotherapy; Fungizone ; Intralipid ; Leishmania infantum; Leishmaniasis; Lipid formulations; Mice

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; INTRALIPID; MEGLUMINE ANTIMONATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEISHMANIA INFANTUM; MOUSE; NONHUMAN; PROMASTIGOTE; SIDE EFFECT; VISCERAL LEISHMANIASIS;

ANIMALIA; LEISHMANIA INFANTUM; MURINAE;

EID: 0029858030     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-9203(96)90330-2     Document Type: Article

References (29)

1. Adler-Moore, J. P., Chiang, S. M., Satorius, A., Guerra, D., McAndrews, B., McManus, E. J. & Proffitt, T. (1991). Treatment of murine candidosis and cryptococcosis with unilamellar liposomal amphotericin B formulation (Am-Bisome). Journal of Antimicrobial Chemotherapy 28, supplement B, S63-S71.
2. Bryceson, A. D. M. (1987). Therapy in man. In: The Leishmaniases in Biology and Medicine, Peters, W. & Killick-Kendrick, R. (editors). London: Academic Press, vol. 2, pp. 847-907.
3. Buffet, P. A., Sulahian, A., Garin, Y. J. F., Nassar, N. & Derouin, F. (1995). Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrobial Agents and Chemotherapy, 39, 2167-2168.
4. Caillot, D., Casasnovas, O., Solary, E., Chavanet, P., Bonnette, B., Reny, G., Entezam, F., Lopez, J., Bonnin, A. & Guy, H. (1993). Efficacy and tolerance of an amphotericin B lipid (Intralipid 20%) emulsion in the treatment of candidaemia in neutropenic patients. Journal of Antimicrobial Chemotherapy, 31, 161-169.
5. Clark, J. M., Whitney, R. R., Oslen, S. J., Goerge, R. J., Swerdel, M. R., Kunselman, L. & Bonner, D. (1991). Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrobial Agents and Chemotherapy, 35, 615-621.
6. Cook, G. C. (1993). Leishmaniasis: some recent developments in chemotherapy. Journal of Antimicrobial Chemotherapy, 31, 327-330.
7. Croft, S. L., Davidson R. N. & Thornton, E. A. (1991). Liposomal amphotericin B in the treatment of visceral leishmaniasis. Journal of Antimicrobial Chemotherapy, 28, supplement B, S111-S118.
8. Davidson, R. N. & Russo, R. (1994). Relapse of visceral leishmaniasis in patients who were coinfected with human immunodeficiency virus and who received treatment with liposomal amphotericin B. Clinical Infectious Diseases, 19, 560.
9. Davidson, R. N., Croft, S., Scott, A., Maini, M., Moody A. H. & Bryceson, A. D. M. (1991). Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet, 337, 1061-1062.
10. Davidson, R. N., Di Martino, L., Gradoni, L., Giacchino, R., Russo, R., Gaeta, G. B., Pempinello, R., Scott, S., Raimondi, F., Cascio, A., Prestileo, T., Caldeira, L., Wilkinson, R. J. & Bryceson, A. D. M. (1994). Liposomal amphotericin B (Am-Bisome) in Mediterranean visceral leishmaniasis: a multicentre trial. Quarterly Journal of Medicine, 87, 75-81.
11. De Marie, S., Jannknegt, R. & Bakker-Woudenberg, I. A. J. M. (1994). Clinical use of liposomal and lipid-complexed amphotericin B. Journal of Antimicrobial Chemotherapy, 33, 907-916.
12. Dereure, J., Reynes, J., Pratlong, F., Lamaury, I., Rioux, J. A., Janbon, F. & Dedet, J. P. (1995). Visceral leishmaniasis in HIV-infected patients in the South of France. Bulletin of the World Health Organization, 73, 245-246.
13. Gangneux, J. P., Sulahian, A., Garin, Y. J. F. & Derouin, F. (1996). Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of the efficacy of AmBisome. Antimicrobial Agents and Chemotherapy, 40, 1214-1218.
14. Giacchino, R., Giambartolomei, G., Tasso, L., Timitilli, A., Castagnola, E., Brisigotti, M. & Micalizzi, C., (1993). Treatment with liposomal amphotericin B of a child affected with drug-resistant visceral leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 87, 310.
15. Gradoni, L., Davidson, R. N., Orsini, S., Betto, P. & Giambenedetti, M. (1993). Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice. Journal of Drug Targeting, 1, 311-316.
16. Gradoni, L., Bryceson, A. & Desjeux, P. (1995). Treatment of Mediterranean visceral leishmaniasis. Bulletin of the World Health Organization, 73, 191-197.
17. Heinemann, V., Kähny, B., Debus, A., Wachloz, K., & Jehn, U. (1994). Pharmacokinetics of liposomal amphotericin B (Am-Bisome) versus other lipid-based formulations. Bone Marrow Transplantation, 14, supplement 5, S8-S9.
18. Janknegt, S., de Marie, S., Bakker-Woudenberg, I. A. J. M. & Crommelin, D. J. A. (1992). Liposomal and lipid formulations of amphotericin B. Clinical Pharmacokinetics, 23, 279-291.
19. Janoff, A. S., Boni, L. T., Popescu, M. C., Minchey, S. R., Culis, P. R., Madden, T. D., Taraschi, T., Gruner, S. M., Shyamsunder, E., Tate, M. W., Mendelsohn, R. & Bonner, D. (1988). Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proceedings of the National Academy of Sciences of the USA, 85, 6122-6126.
20. Joly, V., Geoffray, C., Reynes, J., Goujard, C., Mechali, D. & Yeni, P. (1993). A pilot study of deoxycholate amphotericin B associated with Intralipid 20% in the treatment of cryptococcal meningitis in patients with AIDS. In: Program and Abstracts of the Thirty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 1993. Washington, DC: American Society for Microbiology, abstract 814, p.268.
21. Khoo, S. H., Bond, J. & Denning, D. W. (1994). Administering amphotericin B - a practical approach. Journal of Antimicrobial Chemotherapy, 33, 203-213.
22. Lazanas, M. C., Tsekes, G. A., Papandreou, S., Harhalakis, N., Scandall, A., Nikiforakis, E. & Saroglou, G. (1993). Liposomal amphotericin B for leishmaniasis treatment of AIDS patients unresponsive to antimonial compounds. AIDS, 7, 1019.
23. Mishra, M., Biswas, U. K., Jha, A. M. & Khan, A. B. (1994). Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet, 344, 1599-1600.
24. Moreau, P., Milpied, N., Fayette, N., Ramée, J. F. & Harousseau, J. L. (1992). Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with Intralipid 20% compared with conventional amphotericin B in neutropenic patients. Journal of Antimicrobial Chemotherapy, 30, 535-541.
25. Proffitt, R. T., Satorius, A., Chiang, S. M., Sullivan, L. & Adler-Moore, J. P. (1991). Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. Journal of Antimicrobial Chemotherapy, 28, supplement B, S49-S61.
26. Rosenthad, E., Marty, P., Poizot-Martin, I., Reynes, J., Pratlong, F., Lafeuillade, A., Jaubert, D., Boulat, O., Dereure, J., Gambarelli, F., Gastaut, J.A., Dujardin, P., Dellamonica, P. & Cassuto, J.-P. (1995). Visceral leishmaniasis and HIV-1 co-infection in southern France. Transactions of the Royal Society of Tropical Medicine and Hygiene, 89, 159-162.
27. Swenson, C. E., Bolcsak, L. E., Perkins, W. R. & Janoff, A. S. (1995). Lipid based formulations of amphotericin B. Journal of Antimicrobial Chemotherapy, 35, 709-711.
28. Thakur, C. P., Sinha, G. P., Barat, D. & Singh, R. K. (1994). Are incremental doses of amphotericin B required for the treatment of visceral leishmaniasis? Annals of Tropical Medicine and Parasitology. 88, 365-370.
29. Torre-Cisneros, J., Villanueva, J. L., Kindelan, J. M., Jurado, R. & Sanchez-Guijo, P. (1993). Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus. Clinical Infectious Diseases, 17, 625-627.